Belatacept and Autoimmune Adverse Events.
作者信息
Ville Simon, Cantarovich Diego
机构信息
Institut of Transplantation, Urology and Nephrology, Nantes University Hospital, Nantes, France.
出版信息
Transplantation. 2018 Jul;102(7):e355-e356. doi: 10.1097/TP.0000000000002247.
Abstract
摘要
相似文献
1
Belatacept and Autoimmune Adverse Events.
Transplantation. 2018 Jul;102(7):e355-e356. doi: 10.1097/TP.0000000000002247.
2
Recurrent ANCA-associated vasculitis after renal transplantation.
Transplantation. 2010 Dec 15;90(11):1239-40. doi: 10.1097/TP.0b013e3181f9256a.
3
Belatacept as maintenance therapy in kidney transplant recipients with ANCA-associated vasculitis.
Clin Exp Rheumatol. 2021 Mar-Apr;39 Suppl 129(2):194-195. doi: 10.55563/clinexprheumatol/7jue09. Epub 2021 Mar 18.
4
Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.
Expert Rev Clin Pharmacol. 2016;9(2):215-27. doi: 10.1586/17512433.2016.1112736. Epub 2015 Dec 22.
5
Recurrent Psoriasis After Introduction of Belatacept in 2 Kidney Transplant Recipients.
Prog Transplant. 2016 Jun;26(2):109-11. doi: 10.1177/1526924816640674.
6
Stricturing Crohn's disease-like colitis in a patient treated with belatacept.
World J Gastroenterol. 2017 Dec 28;23(48):8660-8665. doi: 10.3748/wjg.v23.i48.8660.
7
Hepatitis B virus reactivation during belatacept treatment after kidney transplantation.
Transpl Infect Dis. 2019 Dec;21(6):e13170. doi: 10.1111/tid.13170. Epub 2019 Sep 19.
8
Recurrence of anti-neutrophil cytoplasmic antibody vasculitis in the kidney allograft.
Nephrology (Carlton). 2012 Apr;17 Suppl 1:16-9. doi: 10.1111/j.1440-1797.2012.01586.x.
9
Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression.
J Nephrol. 2023 May;36(4):1169-1174. doi: 10.1007/s40620-022-01556-x. Epub 2023 Jan 4.
10
Belatacept in the treatment of acute T-cell mediated rejection and maintenance immunosuppression in a paediatric kidney transplant recipient.
Nephrology (Carlton). 2022 Jul;27(7):641-642. doi: 10.1111/nep.14036. Epub 2022 Mar 14.
引用本文的文献
1
Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database.
BMC Pharmacol Toxicol. 2025 Aug 11;26(1):147. doi: 10.1186/s40360-025-00972-6.
2
Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression.
J Nephrol. 2023 May;36(4):1169-1174. doi: 10.1007/s40620-022-01556-x. Epub 2023 Jan 4.
3
Psoriasis in the transplant population.
Arch Dermatol Res. 2023 Jul;315(5):1109-1128. doi: 10.1007/s00403-022-02487-0. Epub 2022 Dec 2.
本文引用的文献
1
Stricturing Crohn's disease-like colitis in a patient treated with belatacept.
World J Gastroenterol. 2017 Dec 28;23(48):8660-8665. doi: 10.3748/wjg.v23.i48.8660.
2
Psoriatic skin lesions induced by abatacept: Case report and review of the published work.
J Dermatol. 2017 Jul;44(7):845-846. doi: 10.1111/1346-8138.13550. Epub 2016 Aug 20.
3
Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
Front Immunol. 2015 Aug 10;6:411. doi: 10.3389/fimmu.2015.00411. eCollection 2015.
4
High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.
Am J Transplant. 2014 Mar;14(3):607-14. doi: 10.1111/ajt.12600.
5
Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans.
Transplantation. 2013 Oct 27;96(8):689-96. doi: 10.1097/TP.0b013e31829f1607.
Zotero 插件